Article Figures & Data
Figures
- FIGURE 1.
Number of abnormal findings revealed by 99mTc-TOC and 111In-OCT in 31 patients.
- FIGURE 2.
A 51-y-old man (patient 23) with multiple liver metastases of small bowel carcinoid. Matching tracer accumulations are shown by 99mTc-TOC and 111In-OCT on anterior views (99mTc-TOC 4 h after injection [A] and 111In-OCT 24 h after injection [B]) as well as on SPECT (99mTc-TOC 4 h after injection [C] and 111In-OCT 24 h after injection [D]).
- FIGURE 3.
A 66-y-old woman (patient 14) with papillary thyroid cancer. SSTR scintigraphy with 99mTc-TOC (A) shows clear uptake in solitary metastasis in right lung. 111In-OCT scan was negative 4 and 24 h after injection (B).
- FIGURE 4.
A 69-y-old woman (patient 34) monitored 2 y after surgical treatment of small bowel carcinoid. On 99mTc-TOC scan, focal uptake (A), highly suspicious for tumor recurrence, was observed in abdomen (arrow). 111In-OCT images were negative at 4 h (B) and 24 h (C) after injection. Further investigations could not confirm this abnormal finding; 99mTc-TOC scan result was considered false.
- FIGURE 5.
Statistical analysis of tumor-to-organ ratios in matching studies with pathologic uptake (n = 21).
Tables
Patient no. Sex Age (y) Pathology Indication* Interval† (d) Confirmation 1 M 55 Papillary thyroid carcinoma SSTR status 2 CT 2 F 55 Carcinoid syndrome Detection 21 CT, MRI 3 M 67 GEP tumor Follow-up 22 CT 4 F 39 Medullary thyroid carcinoma SSTR status 3 CT 5 F 66 Small bowel carcinoid Staging 2 CT 6 M 43 Small bowel carcinoid Staging 2 CT 7 M 55 Ectopic Cushing syndrome Detection 17 MRI, endoscopy 8 M 74 Papillary thyroid carcinoma SSTR status 2 CT 9 F 51 Suspected gastrinoma Detection 7 MRI, endoscopy 10 F 52 GEP tumor Staging 2 CT 11 F 75 Follicular thyroid carcinoma SSTR status 2 CT 12 M 58 Papillary thyroid carcinoma SSTR status 2 CT 13 M 45 Paraganglioma Follow-up 19 CT 14 F 66 Papillary thyroid carcinoma SSTR status 11 CT, biopsy 15 F 64 Suspected gastrinoma Detection 15 CT, endoscopy 16 M 41 Islet cell tumor Staging 19 CT 17 F 62 Carcinoid of papilla of Vater Staging 2 CT 18 M 66 Medullary thyroid carcinoma Staging 2 CT, MRI 19 M 67 Medullary thyroid carcinoma SSTR status 2 CT 20 M 56 Follicular thyroid carcinoma SSTR status 3 CT 21 F 58 Bronchogenic carcinoid SSTR status 6 CT, biopsy 22 F 75 Follicular thyroid carcinoma SSTR status 8 CT 23 M 51 Small bowel carcinoid Staging 5 CT, endoscopy 24 F 47 GEP tumor Staging 22 CT 25 M 63 GEP tumor Staging 19 CT 26 F 39 GEP tumor Staging 11 CT 27 M 55 Small bowel carcinoid Staging 4 CT, MRI 28 M 56 GEP tumor Staging 13 CT 29 M 53 Suspected gastrinoma Detection 17 CT, endoscopy 30 F 29 Carcinoid of appendix Follow-up 12 CT 31 M 64 Follicular thyroid carcinoma SSTR status 2 CT 32 F 58 GEP tumor Staging 10 CT 33 F 65 Carcinoid syndrome Detection 5 CT, endoscopy 34 F 69 Small bowel carcinoid Follow-up 10 CT, endoscopy 35 F 68 GEP tumor Staging 21 CT, second look 36 F 50 Carcinoid of rectum Staging 11 CT 37 M 45 Carcinoid of pancreas Staging 14 CT 38 F 54 Pituitary adenoma Follow-up 2 MRI, biopsy 39 M 53 Small bowel carcinoid Staging 9 CT, MRI 40 M 71 Small bowel carcinoid Staging 22 CT 41 F 46 GEP tumor Staging 2 CT ↵* Detection = detection and localization of suspected neuroendocrine tumors and their metastases; Staging = staging patients with neuroendocrine tumors; SSTR status = determination of SSTR status; Follow-up = follow-up studies after successful therapy.
↵† Time interval between both studies.
GEP tumor = (nonfunctioning) neuroendocrine gastroenteropancreatic tumor.
Group n 99mTc-TOC 111In-OCT TP TN FP FN TP TN FP FN Detection 6 0 0 1 5 0 1 0 5 Staging 84 78 0 1 5 67 0 1 16 SSTR status 29 21 0 0 8 20 0 0 9 Follow-up 6 3 2 1 0 3 3 0 0 Overall 125 102 2 3 18 90 4 1 30 TP = true-positive; TN = true-negative; FP = false-positive; FN = false-negative.
Group n 99mTc-TOC 111In-OCT TP TN FP FN TP TN FP FN Detection 6 0 0 1 5 0 1 0 5 Staging 19 17 0 1 1 12 0 1 6 SSTR status 11 8 0 0 3 7 0 0 4 Follow-up 5 2 2 1 0 2 3 0 0 Overall 41 27 2 3 9 21 4 1 15 TP = true-positive; TN = true-negative; FP = false-positive; FN = false-negative.
In this issue
Jump to section
Related Articles
Cited By...
- 18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use
- 18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use
- Improving Contrast and Detectability: Imaging with [55Co]Co-DOTATATE in Comparison with [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE
- International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
- Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms
- Preclinical Evaluation of a High-Affinity 18F-Trifluoroborate Octreotate Derivative for Somatostatin Receptor Imaging
- Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
- Patient-Specific Radiation Dosimetry of 99mTc-HYNIC-Tyr3-Octreotide in Neuroendocrine Tumors
- 99mTc-HYNIC-TOC Scintigraphy Is Superior to 131I-MIBG Imaging in the Evaluation of Extraadrenal Pheochromocytoma
- Initial Direct Comparison of 99mTc-TOC and 99mTc-TATE in Identifying Sites of Disease in Patients with Proven GEP NETs
- 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
- Evaluation of [99mTc/EDDA/HYNIC0]Octreotide Derivatives Compared with [111In-DOTA0,Tyr3, Thr8]Octreotide and [111In-DTPA0]Octreotide: Does Tumor or Pancreas Uptake Correlate with the Rate of Internalization?
- Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status
- Imaging of Advanced Neuroendocrine Tumors with 18F-FDOPA PET
- Two-Step Methodology for High-Yield Routine Radiohalogenation of Peptides: 18F-Labeled RGD and Octreotide Analogs